Sudeep Pharma Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Sudeep Pharma Ltd filed with BSE on 11 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Sudeep Pharma reported Q1 FY27 revenue growth of 27% year-on-year to Rs 158.3 crores, with EBITDA up 25% to Rs 54.9 crores and profit after tax rising to Rs 40.6 crores. Growth was driven by the pharma, food and nutrition segment which grew 31%, while specialty ingredients grew 19%, partly held back by an LPG supply shortage in April and early May. Management also discussed progress at the Sudeep Advanced Materials battery-chemicals project, the performance of the NSS European subsidiary, and a phosphoric acid price increase during the quarter.
Numbers mentioned
Revenue: INR158.3 crores (Q1 FY27)
p. 7
“Revenue growth from operation increased by 27% year-on-year to INR158.3 crores in Q1 FY '27 compared to INR124.9 crores in Q1 FY '26.”
Ketan Vyas, page 7 of the filed PDF · View the filing
EBITDA: INR54.9 crores (Q1 FY27)
p. 7
“EBITDA grew by 25% year-on-year to INR54.9 crores from INR43.9 crores in Q1 FY '26.”
Ketan Vyas, page 7 of the filed PDF · View the filing
EBITDA margin: 34.7% (Q1 FY27)
p. 7
“EBITDA margin remain resilient at 34.7%, demonstrating the company's ability to sustain operational efficiency and cost discipline while scaling the business.”
Ketan Vyas, page 7 of the filed PDF · View the filing
Profit after tax: INR40.6 crores (Q1 FY27)
p. 7
“Profit after tax increased to INR40.6 crores compared to INR31.3 crores in the corresponding quarter last year.”
Ketan Vyas, page 7 of the filed PDF · View the filing
PAT margin: 25.6% (Q1 FY27)
p. 7
“PAT margin improved to 25.6% from 25%, reflecting enhanced operating leverage and efficient capital management.”
Ketan Vyas, page 7 of the filed PDF · View the filing
Pharma, food and nutrition segment revenue growth: 31% (Q1 FY27)
p. 4
“Our pharma, food and nutrition business remained our largest business segment and started the year with a strong quarter with revenues growing 31% year-on-year.”
Shanil Bhayani, page 4 of the filed PDF · View the filing
Specialty ingredients segment revenue growth: 19% (Q1 FY27)
p. 5
“Our specialty ingredients business delivered 19% year-on-year growth during the quarter.”
Shanil Bhayani, page 5 of the filed PDF · View the filing
Pharma, food and nutrition share of revenue: 69% (Q1 FY27)
p. 7
“The pharma and food nutrition segment continued to be primary revenue contributor for this quarter, accounting for 69% of Q1 FY '27 revenue compared to 66% in Q1 FY '26.”
Ketan Vyas, page 7 of the filed PDF · View the filing
Specialty ingredient share of revenue: 31% (Q1 FY27)
p. 7
“Specialty ingredient contributed 31%, indicating a balanced and diverse product portfolio.”
Ketan Vyas, page 7 of the filed PDF · View the filing
Phosphoric acid price increase: approximately 50% (Q1 FY27)
p. 4
“Continued logistics disruptions, elevated freight costs, and a sharp increase in sulfur prices resulted in phosphoric acid price increasing by approximately 50% during the quarter.”
Shanil Bhayani, page 4 of the filed PDF · View the filing
Battery material customer qualification funnel: 21 customers at lab validation, 16 at pilot-scale, 7 at pre-commercial/commercial validation (Q1 FY27)
p. 6
“Today, 21 customers are at the laboratory validation stage, 16 customers have progressed to pilot-scale evaluation, and 7 customers have successfully completed pre-commercial or commercial validation and are currently engaging in active off-take discussions.”
Shanil Bhayani, page 6 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
EBITDA margin — 37% to 38%
stated as an aspiration by Shanil Bhayani
p. 5
“As these conditions gradually normalize, we believe our international business remains well-positioned to continue growing while contributing positively to our overall margin profile and supporting our target to sustain EBITDA margins between 37% and 38%.”
Shanil Bhayani, page 5 of the filed PDF · View the filing
NSS margin — similar margins as core specialty ingredients business · by FY28
stated as an aspiration by Shanil Bhayani
p. 5
“we continue to believe it represents a compelling long-term strategic asset and expect both growth and profitability to improve as European market conditions normalize and integration benefits begin to materialize, with a target for NSS to deliver similar margins as our core specialty ingredients business by FY '28.”
Shanil Bhayani, page 5 of the filed PDF · View the filing
Sudeep Advanced Materials Phase 1 commissioning — Phase 1 commissioning · April 2027
stated firmly by Shanil Bhayani
p. 5
“Construction remains on schedule, and we continue to target commissioning of Phase 1 by April 2027.”
Shanil Bhayani, page 5 of the filed PDF · View the filing
Long-lead equipment deliveries — completion of major long-lead equipment deliveries · this October
stated firmly by Shanil Bhayani
p. 5
“Deliveries of all major long-lead equipment are expected to be completed this October, while statutory approvals continue to progress in line with our project schedule.”
Shanil Bhayani, page 5 of the filed PDF · View the filing
Binding off-take agreements — two significant binding off-take agreements · later this year
stated conditionally by Shanil Bhayani
p. 6
“Based on the progress of ongoing commercial discussions, we remain optimistic about concluding two significant binding off-take agreements later this year.”
Shanil Bhayani, page 6 of the filed PDF · View the filing
Phase 2 and Phase 3 planning acceleration
stated conditionally by Shanil Bhayani
p. 6
“Subject to these agreements, we also expect to accelerate planning for our Phase 2 and Phase 3 expansions to support future customer demand.”
Shanil Bhayani, page 6 of the filed PDF · View the filing
Battery materials capacity expansion — 200 KTPA · between calendar year 2030 and 2031
stated as an aspiration by Shanil Bhayani
p. 9
“Current planning is not FY30, but in terms of between calendar year '30 and '31, we would be able to the current target is to be at 200 KTPA.”
Shanil Bhayani, page 9 of the filed PDF · View the filing
Specialty ingredients business recovery — return to historical growth trajectory · beginning Q2
stated firmly by Shanil Bhayani
p. 5
“As a result, we expect this business to return to its historical growth trajectory beginning the second quarter.”
Shanil Bhayani, page 5 of the filed PDF · View the filing
Greenfield facility supply start — supplies to start from new facility · Q3
stated conditionally by Shanil Bhayani
p. 8
“We expect that approval to come in this quarter as well, and for supplies to start from this facility in Q3.”
Shanil Bhayani, page 8 of the filed PDF · View the filing
Working capital cycle — closer to 150 days · long-term
stated as an aspiration by Shanil Bhayani
p. 18
“In the near term, the long-term sustainable would be closer to 150 days.”
Shanil Bhayani, page 18 of the filed PDF · View the filing
Steady-state capacity utilization — between 70% and 75%
stated as an aspiration by Shanil Bhayani
p. 18
“Optimum utilization is between 70% and 75% depending on the product mix that we are running.”
Shanil Bhayani, page 18 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said growth was predominantly volume-driven with about 3% from currency change, and price increases will show up in Q2.
Answered by Shanil Bhayani
Asked by Sanjesh Jain: How much of the pharma, food and nutrition growth was driven by pricing versus volume?
p. 8
“So, predominantly, the growth was volume-driven. I would say approximately around 3% of the growth comes from not necessarily price increase, but just currency change.”
Shanil Bhayani, page 8 of the filed PDF · View the filing
Management said significant growth is expected over the next 2-3 years rather than the current year, as they scale supplies to two large North American customers.
Answered by Shanil Bhayani
Asked by Sanjesh Jain: What is the visibility for the bisglycinate portfolio this year?
p. 8
“we believe in the next 2 or 3 years, it will become -- maybe it will probably be the top two or three revenue-contributing products for the pharma, food, nutrition category.”
Shanil Bhayani, page 8 of the filed PDF · View the filing
Management attributed the drop to sub-50% utilization due to LPG shortage and a weak NSS quarter, noting core specialty margin excluding NSS was in the mid-30s.
Answered by Shanil Bhayani
Asked by Sanjesh Jain: Why did specialty margin fall to 26%?
p. 9
“NSS has had a tough, challenging quarter, and that has kind of dragged down the profitability to the 26% level.”
Shanil Bhayani, page 9 of the filed PDF · View the filing
Management said they have gone from six to eight qualified customers this quarter, all existing large Korean and American companies.
Answered by Shanil Bhayani
Asked by Nirali Shah: How does the battery materials qualification funnel look now?
p. 10
“Today, we received one or two more approvals in the current quarter or in Q1, so we are now qualified with eight.”
Shanil Bhayani, page 10 of the filed PDF · View the filing
Management explained that a large infant formula customer scaled down European operations due to the energy crisis, and NSS is diversifying markets and using Sudeep India's supply chain to improve resilience.
Answered by Shanil Bhayani
Asked by Viraj Shah: What is causing NSS's customer issues and how will margins be improved?
p. 11
“Due to the current energy crisis, that customer has scaled down operation significantly in Ireland, which is kind of -- while we have POs, they've delayed the buying.”
Shanil Bhayani, page 11 of the filed PDF · View the filing
Management said utilization was about a third in April and below 50% in half of May before normalizing.
Answered by Shanil Bhayani
Asked by Shreya Chatterjee: What was capacity utilization this quarter due to the LPG crisis?
p. 16
“So, as LPG there was short supply, largely April, we were at a third utilization of our, what we typically consume. Half of May, we were below 50%, so overall for the quarter, we were significantly underutilizing our capacity, which has now largely reversed, and we are back to normal operations in Q2.”
Shanil Bhayani, page 16 of the filed PDF · View the filing
Management said the near-term target is 160-170 days, excluding battery inventory, with a long-term sustainable target of 150 days.
Answered by Shanil Bhayani
Asked by Shreya Chatterjee: What is the target working capital cycle?
p. 17
“I had mentioned that the target was to come down to maybe 170-odd days, but this would be ex to everything that we're doing in battery.”
Shanil Bhayani, page 17 of the filed PDF · View the filing
Management said Sudeep will not source phosphoric acid from China to remain FEOC compliant, sourcing instead from India and three other countries.
Answered by Shanil Bhayani
Asked by Vinod: Is the company dependent on China for phosphoric acid supply for the battery business?
p. 19
“So, we will not be sourcing any phosphoric acid from China. That is a prerequisite for us for Sudeep or Sudeep Advanced Materials to be FEOC compliant and to supply into the US market that we do not have any supply chains from China.”
Shanil Bhayani, page 19 of the filed PDF · View the filing
Risks flagged
Geopolitical uncertainty, gas supply constraints, elevated logistics costs and supply chain disruption
p. 3
“This performance was achieved despite a challenging global operating environment characterized by geopolitical uncertainties, intermittent gas supply constraints, elevated logistics costs and continued supply chain disruption.”
Sujit Bhayani, page 3 of the filed PDF · View the filing
Sharp increase in phosphoric acid prices due to sulfur price rise and logistics disruption
p. 4
“Continued logistics disruptions, elevated freight costs, and a sharp increase in sulfur prices resulted in phosphoric acid price increasing by approximately 50% during the quarter.”
Shanil Bhayani, page 4 of the filed PDF · View the filing
LPG supply shortage disrupting specialty ingredients production
p. 5
“This was primarily due to temporary operational constraints arising from the LPG supply shortage during April and the first half of May.”
Shanil Bhayani, page 5 of the filed PDF · View the filing
Challenging European operating environment affecting NSS
p. 5
“Turning to NSS, the operating environment in Europe remains challenging. Elevated energy costs and subdued industrial production have continued to impact customer demand across several end markets, resulting in a slower recovery.”
Shanil Bhayani, page 5 of the filed PDF · View the filing
NSS customer scaling down operations due to energy crisis, delaying purchase orders
p. 11
“Due to the current energy crisis, that customer has scaled down operation significantly in Ireland, which is kind of -- while we have POs, they've delayed the buying.”
Shanil Bhayani, page 11 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.